Multicenter, randomized controlled clinical trial of biapenem in the treatment of acute bacterial infections
10.3969/j.issn.1001-6821.2010.02.001
- VernacularTitle:比阿培南治疗急性细菌性感染的多中心随机对照临床试验
- Author:
Feng DU
1
;
Xue-Song SU
;
Xiao-Hui BIAN
;
De-Tian LI
Author Information
1. 中国医科大学附属盛京医院
- Keywords:
biapenem;
imipenenr/cilastatin;
bacterial infection
- From:
The Chinese Journal of Clinical Pharmacology
2010;26(2):83-88
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of biapenem versus imipenem/cilastatin in the treatment of acute bacterial infections.Methods A multicenter,randomized,controlled clinical trial was carried out.In the study,135 proper patients were enrolled in biapenem (trial group),while 137 proper patients were enrolled in imipenem/cilastatin(control group).The daily dose of biapenem and imipenem/cilastatin are 600 mg and 1500 mg respectively.The treatment duration for both groups was from 7 to 14 days.Results The cure rate for trial and control was separately 62.79%and 55.64%.The effective rate for trial and control was separately 93.8%and 88.72%.The bacterial eradication rate for trial and control was separately 90.41%and 88.33%.The incidence of drug adverse reaction was 10.37%and 11.03%,respectively.Conclusion Biapenem is both effective and safe drug for acute bacterial infection.
